Year End message from Immunovia´s CEO Mats Grahn
As the snow falls over Immunovia’s facilities in Lund, Sweden and Marlborough, USA, season’s greetings from all of us!
We’d like to invite all of our investors, collaborators, supporters and suppliers to join in celebrating what has been a year of great progress.
Over the last year, we have continued our mission to develop and validate accurate blood-based diagnostic tests that make a real and significant impact on healthcare worldwide. Immunovia does this by detecting major diseases at an early enough stage to enable successful intervention. A postponement regarding our lead product IMMray™ PanCan-d for pancreatic cancer has been more than counterbalanced by the willingness of leading centres of excellence across the US and Europe to join our extensive trial programmes – particularly the prospective PanFAM-1 study of familial risk for pancreatic cancer which now is the largest ever of its kind.
Beginning of this year, we started PanDIA-1, the world’s largest study of new onset diabetic patients in a prospective pancreatic cancer study supported by Swedish Government Programme SWElife. Sample collection providing access of up to 6 000 new onset diabetic patients is based on a collaboration including Sweden’s two major universities Lund and Uppsala, Lund University Diabetic Center, as well as Skåne and Uppsala healthcare regions. The third clinical study, PanSYM-1, is a large clinical study in collaboration with University College of London, UK, has already provided us with several hundreds of samples from high risk patients with symptoms suggestive of pancreatic cancer, these samples will now be analysed with IMMray™ PanCan-d and be included as part of the validation programme during 2019.
In addition, in 2018, we started to extend the utilization of our IMMray™ platform for our product pipeline. We have identified two new strategic focus areas in our ongoing development activities – non-small cell lung cancer (NSLC) and Rheumatoid Arthritis (RA). Both address very large unmet clinical needs, in focus of the global healthcare systems, and thereby represent tremendous commercial opportunities for Immunovia adding to our main focus on earlier detection of pancreatic cancer.
On the corporate side, moving from our initial listing on First North to NASDAQ Stockholm’s main market has given us the platform enabling financial strength and stability to complete our prioritized activities needed for commercialization and extension of the product pipeline.
Last but not least, as a key part of the preparation for commercializing IMMray™ PanCan-d for the early detection of pancreatic cancer, Immunovia has recently completed the expansion of our production and sample testing facilities, IMMray™ Dx Laboratories, at our headquarter site in Lund, Sweden. Further reinforcing the IMMray™ Dx Laboratories at Immunovia’s subsidiary in Marlborough, Massachusetts that opened last year. The new facilities for production and testing provide Immunovia with capacity and capability to produce slides to meet the demands for the commercial testing as well as the large prospective studies needed for reimbursement.
In short, this is the end of an exciting year and the start of 2019 that looks even more promising for the company. We are looking forward with confidence to next year and to continuing to work with you all and wish you a successful and prosperous 2019!
Mats Grahn, CEO, Immunovia